Interventions on metabolic syndrome in postmenopausal women

doi:10.3969/j.issn.1006-7795.2013.04.008

Abstract

Abstract:

Objective To explore the efficacy of hormone therapy and lifestyle intervention in metabolic syndrome of postmenopausal women.Methods A total of 121 voluntary participants were recruited, divided into hormone therapy group which contained 64 persons and lifestyle intervention group which contained 57 persons. Hormone therapy group was treated with estradiol valerate combined with dydrogesterone for 6 months plus lifestyle intervention. Lifestyle intervention group was intervened with dietary nutrition guidance and psychological counseling for 6 months. The Kupperman score, anthropometric indicators, serological indicators and the body fat% were measured before and after the interventions. The paired sample test was conducted between the measurements before and after the intervention in hormone therapy group and lifestyle intervention group respectively. The independent samples test was conducted between the measurements after the intervention in hormone therapy group and lifestyle intervention group.Results All the 121 subjects completed the study, including 64 cases of hormone treatment group and 57 cases of lifestyle intervention group. After 6 months of hormone therapy, Kupperman score, body mass index, waist circumference, body fat, serum follicle-stimulating hormone(FSH), triglycerides(TG), low density lipoprotein cholesterol(LDL-C) of hormone therapy group subjects were significantly decreased, and the estradiol(E2), high density lipoprotein cholesterol(HDL-C) levels were significantly increased compared with lifestyle intervention group subjects, the difference between the two groups was statistically significant. But the total cholesterol(TC), fasting plasma glucose(FPG) level, prevalence of metabolic syndrome(MS) were not significantly different compared with the lifestyle intervention group subjects.Conclusion Both hormone therapy and lifestyle intervention could significantly reduce the prevalence of the MS in menopausal women after 6 months intervention. But the hormone therapy plus lifestyle intervention was better than the lifestyle intervention only in improving the menopausal symptoms, decreasing the weight and the body fat increases, prevention of the occurrence and development of metabolic syndrome components in postmenopausal women.

Key words: menopause, metabolic syndrome, hormone therapy, lifestyle intervention

CLC Number:

RUAN Xiangyan, YAN Dan, ZHANG Junli, LU Yongjun, LIU Shunyu, WANG Juan, YIN Dongmei, LIU Yulan, ZHEN Jie. Interventions on metabolic syndrome in postmenopausal women[J]. Journal of Capital Medical University, 2013, 34(4): 519-524.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.04.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I4/519

References

[1] 宋秀霞.国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志,2005,13(3):178-180.

[2] Alberti K G, Zimmet P, Shaw J. The metabolic syndrome a new world-wide definition[J]. Lancent, 2005,366(9491):1059-1062.

[3] Mathieu P, Despres J P, Pibarot P. The ‘valvulo-metabolic' risk in calcific aortic valve disease[J]. Can J Cardiol, 2007,23(Suppl B):32B-39B.

[4] Leuzzi C, Marzullo R, Modena M G. Is meno pause a risk factor for ischemic heart disease in women?[J]. G Ital Cardiol, 2012,13(6):401-406.

[5] Ijuin H, Douchi T, Oki T, et al. The contribution of menopause to changes in body-fat distribution[J]. J Obstet Gynaecol Res,1999,25(5):367-372.

[6] Bittner V. Menopause, age, and cardiovascular risk: a complex relationship[J]. Am Coll Cardiol, 2009,54(25):2374-2375.

[7] Coylewright M, Reckelhoff J F, Ouyang P. Menopause and hypertension: an age-old debate[J]. Hypertension, 2008,51(4):952-959.

[8] Kim E S, Menon V. Status of women in cardiovascular clinical trials[J]. Arterioscler Thromb Vasc Biol, 2009,29(3):279-283.

[9] Reckelhoff J F, Maric C. Sex and gender differences in cardiovascular-renal physiology and pathophysiology[J]. Steroids, 2010,75(11):745-746.

[10] Siegel R D, Cupples A, Schaefer E J, et al. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study[J]. Metabolism, 1996,45(10):1267-1272.

[11] Lee S W, Jo H H, Kim M R, et al. Association between metabolic syndrome and serum leptin levels in postmenopausal women[J]. J Obstet Gynaecol, 2012,32(1):73-77.

[12] Chu F L, Hsc C H, Jeng C. Low predictability of anthropometric indicators of obesity in metabolic syndrome(MS) risks among elderly women[J]. Arch Gerontol Geriatr, 2012,55(3):718-723.

[13] Zivkovic T B, Vuksanovic M, Jelic M A, et al. Obesity and metabolic syndrome during the menopause transition in Serbian women[J]. Climacteric, 2011,14(6):643-648.

[14] Lakka H M, Laaksonen D E, Lakka T A, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[J]. JAMA, 2002,288(21):2709-2716.

[15] Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among U.S. adults[J]. Diabetes Care, 2004,27(10):2444-2449.

[16] Ford E S. Risks for all-cause mortality,cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence[J]. Diabetes Care, 2005,28(7):1769-1778.

[17] Mathieu P, Pibarot P, Larose E, et al. Visceral obesity and the heart[J]. Int J Biochem Cell Biol, 2008,40(5):821-836.

[18] Barton M, Meyer M R. Postmenopausal hypertension: mechanisms and therapy[J]. Hypertension, 2009,54:11-18.

[19] Barton M, Meyer M R. Postmenopausal hypertension: mechanisms and therapy[J]. Hypertension, 2009,54(1):11-18.

[20] USPSTF. Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force[J]. Am Fam Physician,2003,67(2):358-364.

[21] Sitges M, Heras M, Roig E, et al. Acute and mid-term combined hormone replacement therapy improves endothelial function in post-menopausal women with angina and angiographically normal coronary arteries[J]. Eur Heart J, 2001,22(22):2116-2124.

[22] 杨红霞,吕美娜.中老年女性心脑血管疾病的危险因素和综合干预措施[J].解放军医药杂志,2012,24(4):64-68.

[23] 张润军,杨丽霞.冠心病危险因素与冠状动脉病变的相关性分析[J].解放军医药杂志,2011,23(1):7-11.